ELUT ELUTIA INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1708527 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.2%
TTM net income YoY305.5%
TTM EPS YoY233.3%
Revenue 3-yr CAGR-26.9%
Net income 3-yr CAGR—
Margins
Gross margin59.0%
Operating margin-279.0%
Net margin546.7%
FCF margin-509.4%
EBITDA margin-265.2%
Returns
ROE—
ROA140.2%
ROIC (approx.)—
Asset turnover0.26x
Leverage & solvency
Liabilities / assets68.2%
Debt / equity0.53x
Current ratio2.63x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.91x
Accruals ratio267.1%
Payout ratio—
Capex / revenue14.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.14M | $2.43M | $3.11M | $3.27M | $944,000 | $2.75M | $2.95M | $2.82M |
| Cost of revenue | $435,000 | $980,000 | $1.31M | $1.36M | $446,000 | $1.29M | $1.57M | $1.49M |
| Gross profit | $702,000 | $1.45M | $1.80M | $1.91M | $498,000 | $1.45M | $1.38M | $1.32M |
| R&D expense | $2.98M | $2.53M | $1.97M | $1.22M | $1.09M | $989,000 | $871,000 | $727,000 |
| SG&A expense | $3.75M | $3.45M | $4.09M | $4.29M | $3.50M | $3.55M | $3.72M | $4.25M |
| Operating income | -$6.90M | -$7.96M | -$6.35M | -$6.56M | -$5.87M | -$8.37M | -$6.78M | -$7.46M |
| Interest expense | — | — | — | — | $265,000 | $518,000 | $1.08M | $1.07M |
| Pretax income | -$6.50M | -$7.64M | -$7.82M | -$6.52M | -$1.04M | -$7.08M | -$1.88M | -$7.15M |
| Income tax | $8,000 | $8,000 | $70,000 | -$11,000 | $8,000 | $8,000 | $8,000 | $2,000 |
| Net income | -$1.28M | -$7.65M | -$7.47M | $70.79M | -$3.87M | -$9.61M | -$3.93M | -$9.06M |
| EBITDA | -$6.49M | -$7.61M | -$6.02M | -$6.26M | -$5.14M | -$7.47M | -$5.91M | -$6.59M |
| EPS (basic) | -0.03 | -0.17 | -0.17 | — | -0.09 | -0.23 | -0.10 | — |
| EPS (diluted) | -0.04 | -0.17 | -0.17 | — | -0.19 | -0.26 | -0.21 | — |
| Weighted avg. shares (diluted) | 47.54M | 44.22M | 43.00M | — | 46.96M | 46.31M | 42.91M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $29.09M | $19.90M | $28.49M | $36.35M | $4.72M | $8.50M | $17.36M | $13.24M |
| Receivables | $1.47M | $1.44M | $2.07M | $1.73M | $3.55M | $3.15M | $2.86M | $2.28M |
| Inventory | $272,000 | $2.65M | $2.66M | $438,000 | $2.01M | $5.24M | $4.29M | $1.93M |
| Current assets | $42.17M | $37.22M | $48.59M | $55.82M | $18.38M | $22.28M | $30.02M | $26.17M |
| PP&E, net | $2.83M | $2.92M | $2.91M | $2.51M | $2.05M | $2.07M | $1.03M | $671,000 |
| Intangibles | $720,000 | $990,000 | $1.26M | $1.53M | $1.80M | $6.58M | $7.42M | $2.60M |
| Total assets | $48.19M | $43.65M | $55.21M | $62.35M | $29.41M | $33.85M | $39.30M | $36.13M |
| Current liabilities | $16.03M | $21.05M | $23.73M | $25.14M | $41.33M | $37.95M | $36.85M | $37.80M |
| Short-term debt | — | — | — | — | $5.00M | $3.75M | $2.50M | $1.25M |
| Long-term debt | $8.10M | — | — | — | $21.10M | $21.37M | $21.76M | $22.60M |
| Total debt | $8.10M | — | — | — | $26.10M | $25.12M | $24.26M | $23.85M |
| Total liabilities | $32.87M | $27.90M | $32.68M | $34.68M | $73.33M | $75.69M | $75.76M | $82.39M |
| Shareholders' equity | $15.32M | $15.75M | $22.53M | $27.67M | -$43.92M | -$41.84M | -$36.46M | -$46.26M |
| Net debt | -$21.00M | — | — | — | $21.38M | $16.62M | $6.90M | $10.61M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.13M | -$8.46M | -$7.83M | -$24.81M | -$2.89M | -$8.23M | -$8.88M | -$12.26M |
| Capital expenditure | $42,000 | $91,000 | $459,000 | $854,000 | $630,000 | $114,000 | $278,000 | $94,000 |
| Free cash flow | -$8.17M | -$8.55M | -$8.29M | -$25.67M | -$3.52M | -$8.34M | -$9.16M | -$12.35M |
| Investing cash flow | $7.66M | -$91,000 | -$34,000 | $79.58M | -$630,000 | -$114,000 | -$278,000 | -$94,000 |
| Financing cash flow | $9.67M | -$40,000 | $3,000 | -$23.14M | -$262,000 | -$516,000 | $13.28M | -$151,000 |
| Depreciation & amortization | $403,000 | $349,000 | $330,000 | $297,000 | $728,000 | $892,000 | $868,000 | $863,000 |
| Stock-based compensation | $860,000 | $905,000 | $931,000 | $872,000 | $1.33M | $1.03M | $1.21M | $1.21M |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.